Arecor Therapeutics (LSE:AREC) Ending Cash Position : £5.09 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Ending Cash Position?

Arecor Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was £5.09 Mil.

Arecor Therapeutics's quarterly Ending Cash Position increased from Dec. 2022 (£4.77 Mil) to Jun. 2023 (£6.61 Mil) but then declined from Jun. 2023 (£6.61 Mil) to Dec. 2023 (£5.09 Mil).

Arecor Therapeutics's annual Ending Cash Position declined from Dec. 2021 (£18.32 Mil) to Dec. 2022 (£4.77 Mil) but then increased from Dec. 2022 (£4.77 Mil) to Dec. 2023 (£5.09 Mil).

Arecor Therapeutics Ending Cash Position Historical Data

The historical data trend for Arecor Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Ending Cash Position Chart

Arecor Therapeutics Annual Data

Trend

May17

May18

May19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

3.45

2.90

18.32

4.77

5.09

Arecor Therapeutics Semi-Annual Data
	May18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial					18.32	13.72	4.77	6.61	5.09

Arecor Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Arecor Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	4.765	+	0.328
	=	5.09

Arecor Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	6.61	+	-1.517
	=	5.09

Arecor Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.